The study was funded by Pfizer. Dr. Kantarjian disclosed research support from the company. Dr. Izraeli reported having no relevant disclosures.
Conference Coverage
Inotuzumab continues to wow against relapsed/refractory ALL
Publish date: June 12, 2016
At THE EHA CONGRESS